Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Tango Therapeutics, Inc. (NASDAQ: TNGX) announced that its CEO, Barbara Weber, M.D., will participate in a virtual panel on synthetic lethality in cancer therapeutics at the 13th Annual Wedbush PacGrow Healthcare Conference on August 9 at 12:00 PM ET. The event will be accessible via a live webcast on the company's website and will remain available for replay for 30 days after the presentation. Tango is focused on advancing precision cancer therapies through innovative drug targets and leveraging synthetic lethality.

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a virtual panel on synthetic lethality in cancer therapeutics at the 13^th Annual Wedbush PacGrow Healthcare Conference on Tuesday, August 9 at 12:00 PM ET.

A live webcast of the event will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.

About Tango Therapeutics

Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.

Investor Contact:
Sam Martin/Michael Barron
Argot Partners
tango@argotpartners.com

Media Contact:
Joshua R. Mansbach
Argot Partners
tango@argotpartners.com

FAQ

When is Tango Therapeutics' CEO participating in the Wedbush PacGrow Healthcare Conference?

Barbara Weber, CEO of Tango Therapeutics, will participate in the conference on August 9 at 12:00 PM ET.

Where can I watch the Tango Therapeutics presentation during the Wedbush Conference?

The presentation will be available via live webcast on Tango Therapeutics' website under the 'Events & Presentations' tab.

How long will the webcast from the Wedbush Conference be available?

The replay of the webcast will be archived on Tango Therapeutics' website for 30 days following the event.

What is the focus of Tango Therapeutics' research?

Tango Therapeutics is focused on discovering novel drug targets and precision medicine for cancer treatment, utilizing the principle of synthetic lethality.

What is the stock symbol for Tango Therapeutics?

Tango Therapeutics is traded under the stock symbol TNGX.